印度医疗保健公司 Zydus 为印度晚期前列腺癌患者推出了口服、经济实惠的睾酮抑制药 Rexigo™。 Indian healthcare firm Zydus launches oral, affordable testosterone suppression pill Rexigo™ for advanced prostate cancer patients in India.
印度医疗保健公司 Zydus Lifesciences 推出了 Rexigo™，这是第一种用于晚期前列腺癌患者的睾酮抑制每日一次口服药物。 Zydus Lifesciences, an Indian healthcare company, has launched Rexigo™, the first oral once-a-day pill for testosterone suppression in patients with advanced prostate cancer. 这种新疗法比目前的注射疗法更实惠，每月费用为 6,995 卢比。 This new treatment is more affordable than current injectable options, costing Rs 6,995 per month. Rexigo™ 过去四年已在发达国家上市，将为印度的前列腺癌患者提供方便且更容易获得的治疗。 Previously available in developed countries for the past four years, Rexigo™ will provide a convenient and more accessible treatment for prostate cancer patients in India. 2022 年，印度报告了超过 43,000 例前列腺癌病例。 There were over 43,000 reported cases of prostate cancer in India in 2022.